Are Nasal Antihistamines a Substitute for Steroids? No — They're Complementary

TL;DR

No, intranasal antihistamines are not substitutes for intranasal corticosteroids — they are complementary. The 2020 Joint Task Force Rhinitis Practice Parameter identifies intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis 3 Guideline Antihistamines act fast but don’t address the underlying eosinophilic inflammation. Combining azelastine and fluticasone propionate (whether co-administered or as the co-formulated product Dymista / MP29-02) produces greater allergic-rhinitis symptom relief than either agent alone, demonstrated in three Phase III RCTs in moderate-to-severe seasonal allergic rhinitis (n=3,398) 1 Expert

The honest answer

Astepro went OTC in 2021 and immediately patients started asking: do I still need Flonase? The mistake the question makes is treating the two drug classes as interchangeable, when they target different parts of the allergic response.

Histamine is a single mediator released by mast cells. It causes the immediate symptoms of allergic rhinitis — sneezing, itching, runny nose — within minutes of allergen exposure. An H1 antagonist like azelastine blocks the histamine receptor, so the symptoms don’t propagate. Onset is fast, and the relief is fast. In a placebo-controlled trial of azelastine nasal spray 0.15%, onset of symptom relief was reported within 30 minutes of dosing (Shah 2009) 4 Expert

But the allergic cascade has more components: eosinophil recruitment, cytokine release (IL-4, IL-5, IL-13), mast cell stabilization, and chronic mucosal inflammation. Steroids hit all of those. Intranasal corticosteroids work by activating the glucocorticoid receptor inside cells of the nasal lining, which down-regulates recruitment of inflammatory cells (eosinophils, mast cells, T-lymphocytes) and reduces vascular permeability and chemokine release 7 Expert Major U.S. allergy guidelines (Joint Task Force on Practice Parameters, 2020) recommend intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis, including for nasal congestion Guideline

So the question isn’t “should I take Astepro or Flonase?” The right framing is: what does each one do, and do you need both. For mild seasonal allergies, monotherapy is often enough — and a fast-acting antihistamine is reasonable. For persistent or moderate-to-severe disease, the steroid is the daily-control engine, and the antihistamine is the as-needed accelerator.

What the evidence says

The combination data has been robust for over a decade. The headline study is Carr et al 2012 (MP29-02), which directly compared the fixed-dose combo against each component alone.

The mechanistic rationale is straightforward when you separate onset from sustained effect:

The Dymista (azelastine + fluticasone propionate) approval in 2012 was the regulatory recognition that this combination is therapeutically distinct from the components alone. The MP29-02 trial supporting that approval found ~30% greater symptom reduction vs monotherapy, with onset faster than fluticasone alone.

Where Allermi fits

Combination-in-one-bottle is exactly what the literature supports — and it’s the design pattern Dymista pioneered and Allermi extends. Azelastine is a fast-acting intranasal H1-receptor antihistamine that blocks histamine — a chemical released during allergic reactions — to relieve sneezing, itchy nose, runny nose, and nasal congestion Expert

For patients on Astepro + Flonase stacked OTC, Dymista is the FDA-approved fixed-dose alternative; Allermi is the compounded telehealth alternative that can also include ipratropium and micro-dosed oxymetazoline based on symptom profile. See the Astepro vs Dymista and Flonase vs Astepro head-to-heads for picking patterns. Allermi eligibility: 13+ in 39 US states (18+ in AK/NM/OR/SC; not in AR/DE/KS/MS/WV/ND/RI/DC); not prescribed in pregnancy or breastfeeding. Quiz.

Summary & recommendations

Publish history

This page is grounded in primary literature, reviewed by the BestAllergyNasalSprays editorial team. See our editorial methodology and the public claims library.